Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
复制标题
DOI：
10.1126/science.abn7591
复制
发表时间：
2022-02-11
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
全球流行的严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）变体Omicron （B.1.1.529）具有大量突变，特别是在刺突蛋白中，这表明中和抗体的识别可能受到损害。我们对51名接受了两剂或三剂基于信使RNA （mRNA）的COVID-19疫苗BNT162b2的参与者的血清进行了武汉（Wuhan- hu -1参考菌株）、β (B.1.351)、Delta （B.1.617.2）或Omicron假病毒检测。两次给药后，与武汉中和滴度相比，欧米克隆中和滴度降低了22倍。第三次接种后一个月，欧米克隆中和效价较两次接种后提高了23倍，与两次接种后的武汉病毒中和效价水平相似。使用活SARS-CoV-2的一部分参与者的血清证实，需要第三剂疫苗才能有效中和Omicron。这些数据表明，三剂mRNA疫苗BNT162b2可能对ommicron介导的COVID-19有保护作用。令人关注的Omicron （B.1.1.529）变体已被证明比原始的严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）更具传染性和传染性。Muik等人研究了BioNTech/Pfizer的BNT162b2信使RNA （mRNA）疫苗是否对Omicron变体有效。从两组临床试验受试者中收集血清：接受初级两剂BNT162b2疫苗系列（间隔21天）的人，以及在第二剂BNT162b2疫苗后6至18个月接受第三剂“加强”疫苗的人。只接受两次注射的个体对Omicron变体的中和能力较低，而第三次注射BNT162b2显著提高了对Omicron变体的抗体识别。这些数据表明，可能需要三剂量的BNT162b2 mRNA来预防由omicron驱动的COVID-19。接种三剂辉瑞/BioNtech mRNA疫苗BNT162b2的个体的pnk血清可以中和SARS-CoV-2 Omicron变体。
The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)–based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19. The Omicron (B.1.1.529) variant of concern has proven more transmissible and infectious than the original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Muik et al. investigated whether the BioNTech/Pfizer BNT162b2 messenger RNA (mRNA) vaccine is effective against the Omicron variant. Sera were collected from two groups of clinical trial subjects: those who received the primary two-dose BNT162b2 vaccine series (spaced 21 days apart) and those who received a third, “booster” vaccine 6 to 18 months after the second BNT162b2 dose. Individuals who received only two doses had a low ability to neutralize the Omicron variant, whereas a third shot of BNT162b2 significantly improved antibody recognition of Omicron. These data suggest that three BNT162b2 mRNA doses are likely required to protect against Omicron-driven COVID-19. —PNK Sera from individuals vaccinated with three doses of the Pfizer/BioNtech mRNA vaccine BNT162b2 can neutralize the SARS-CoV-2 Omicron variant.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
30.3
作者：
Case, James Brett;Rothlauf, Paul W.;Whelan, Sean P. J.
通讯作者：
Whelan, Sean P. J.
影响因子：
7.2
作者：
Mor O;Zuckerman NS;Hazan I;Fluss R;Ash N;Ginish N;Mendelson E;Alroy-Preis S;Freedman L;Huppert A
通讯作者：
Huppert A
影响因子：
5.8
作者：
Kuzmina A;Wattad S;Khalaila Y;Ottolenghi A;Rosental B;Engel S;Rosenberg E;Taube R
通讯作者：
Taube R
影响因子：
64.8
作者：
Planas, Delphine;Veyer, David;Schwartz, Olivier
通讯作者：
Schwartz, Olivier